2-AMIDO-4-ISOXAZOLYL THIAZOLE COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF
2-Amido-4-isoxazolyl thiazole compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.
1 . A compound of Formula I:
and pharmaceutically acceptable salts, chelates, non-covalent complexes, and mixtures thereof, wherein
R 1 is a 5- to 7-membered cycloheteroalkyl ring which optionally includes 1 or 2 additional heteroatoms chosen from O, S, and N in the ring and where the ring is further substituted with a group R 3 ;
R 2 is chosen from phenyl and substituted phenyl;
Q is chosen from thienyl and substituted thienyl;
A is chosen from 1,3-propylene and 1,4-butylene; and
R 3 is —C(O)NR 4 R 5 wherein R 4 and R 5 are independently chosen from hydrogen, hydroxy, hydroxyethyl, lower alkyl, and lower alkoxy.
2 . The compound of claim 1 having the structure:
3 . The compound of claim 1 having the structure:
4 . The compound of claim 1 wherein R 1 is chosen from pyrrolidine, piperidine, azepane, piperazine, and morpholine, each of which is further substituted with a group R 3 .
5 . The compound of claim 4 wherein R 1 is chosen from piperidine further substituted with a group R 3 .
6 . The compound of claim 1 wherein R 4 is hydrogen.
7 . The compound of claim 1 wherein R 5 is chosen from hydrogen, hydroxy, hydroxyethyl, and lower alkyl.
8 . The compound of claim 7 wherein R 5 is chosen from hydrogen, hydroxy, hydroxyethyl, and methyl.
9 . The compound of claim 1 wherein R 2 is phenyl.
10 . The compound of claim 1 wherein Q is thienyl.
11 . The compound of claim 1 wherein A is 1,3-propylene.
12 . The compound of claim 1 wherein the compound is an inhibitor of at least one ATP-utilizing enzyme.
13 . The compound of claim 12 wherein the at least one ATP-utilizing enzyme is chosen from a human protein kinase.
14 . The compound of claim 13 wherein the human protein kinase is chosen from AKT1 and PIM1 kinase.
15 . The compound of claim 13 wherein the human protein kinase is AKT1.
16 . At least one chemical entity of claim 1 wherein the compound of Formula I is chosen from
(S)-1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)piperidine-2-carboxamide;
(S)-1-(3-(N-(4-(3-phenylisoxazol--yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)-N-hydroxypiperidine-2-carboxamide;
1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)piperidine-2-carboxamide;
(S)-1-(3-(N-(4-(3-phenylisoxazol--yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)-N-(2-hydroxyethyl)piperidine-2-carboxamide;
(S)-1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)-N-methylpiperidine-2-carboxamide;
(S)-1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)pyrrolidine-2-carboxamide;
(S)-1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)-N,N-dimethylpiperidine-2-carboxamide;
1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)pyrrolidine-2-carboxamide;
(S)-1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)-N-methylpyrrolidine-2-carboxamide; and
(S)-1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)-N-tert-butoxypiperidine-2-carboxamide.
17 . A pharmaceutical composition comprising at least one pharmaceutically acceptable vehicle, and a therapeutically effective amount of at least one compound of claim 1 .
18 . The pharmaceutical composition of claim 17 further comprising at least one additional therapeutic agent appropriate for effecting combination therapy.
19 . The pharmaceutical composition of claim 18 wherein said at least one additional therapeutic agent appropriate for effecting combination therapy is chosen from estrogen receptor modulators, cytostatic/cytotoxic agents, anti-proliferative agents, cell cycle checkpoint inhibitors, angiogenesis inhibitors, monoclonal antibody targeted therapeutic agents, tyrosine kinase inhibitors, serine-threonine kinase inhibitors, histone deacetylase inhibitors, heat shock protein inhibitors, and farnesyl transferase inhibitors.
20 . A method of treating cancer in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound of claim 1 , wherein the cancer is glioblastoma, ovarian cancer, breast cancer, endometrial carcinoma, hepatocellular carcinoma, melanoma, colorectal cancer, colon cancer, digestive tract, lung cancer, thyroid, lymphoid, prostate cancer, advanced tumors, hairy cell leukemia, melanoma, chronic myelogenous leukemia, advanced head and neck, squamous cell cancer, metastatic renal cell, non-Hodgkin's lymphoma, metastatic breast, breast adenocarcinoma, advanced melanoma, pancreatic, gastric, non-small cell lung, small cell lung, renal cell carcinoma, multiple myeloma, metastatic prostate, malignant glioma, renal cancer, lymphoma refractory metastatic disease, refractory multiple myeloma, cervical cancer, Kaposi's sarcoma, recurrent anaplastic glioma, or metastatic colon cancer.
21 . The method of claim 20 , further comprising administering at least one additional therapeutic agent appropriate for effecting combination therapy.
22 . The method of claim 21 wherein said at least one additional therapeutic agent appropriate for effecting combination therapy is chosen from estrogen receptor modulators, cytostatic/cytotoxic agents, anti-proliferative agents, cell cycle checkpoint inhibitors, angiogenesis inhibitors, monoclonal antibody targeted therapeutic agents, tyrosine kinase inhibitors, serine-threonine kinase inhibitors, histone deacetylase inhibitors, heat shock protein inhibitors, and farnesyl transferase inhibitors.
23 . A method of inhibiting at least one ATP-utilizing enzyme in a subject comprising administering to the subject at least one compound of claim 1 .
24 . The method of claim 23 wherein the at least one ATP-utilizing enzyme is chosen from a human protein kinase.
25 . The method of claim 24 wherein the human protein kinase is chosen from AKT1 and PIMN kinase.
26 . The method of claim 24 wherein the human protein kinase is AKT1.
27 . A packaged pharmaceutical formulation comprising a pharmaceutical composition of claim 17 and instructions for using the composition to treat a mammal.
28 . The packaged pharmaceutical formulation of claim 27 wherein the instructions are for using the pharmaceutical composition to treat a patient suffering from a disease responsive to inhibition at least one ATP-utilizing enzyme.
29 . The use of at least one compound of claim 1 in the manufacture of a medicament for treating cancer.
30 . The use of claim 29 wherein cancer is glioblastoma, ovarian cancer, breast cancer, endometrial carcinoma, hepatocellular carcinoma, melanoma, colorectal cancer, colon cancer, digestive tract, lung cancer, thyroid, lymphoid, prostate cancer, advanced tumors, hairy cell leukemia, melanoma, chronic myelogenous leukemia, advanced head and neck, squamous cell cancer, metastatic renal cell, non-Hodgkin's lymphoma, metastatic breast, breast adenocarcinoma, advanced melanoma, pancreatic, gastric, non-small cell lung, small cell lung, renal cell carcinoma, multiple myeloma, metastatic prostate, malignant glioma, renal cancer, lymphoma refractory metastatic disease, refractory multiple myeloma, cervical cancer, Kaposi's sarcoma, recurrent anaplastic glioma, or metastatic colon cancer.